DL-Homocysteine
PubChem CID: 778
Connections displayed (default: 10).
Loading graph...
| Compound Synonyms | DL-Homocysteine, 454-29-5, 2-Amino-4-mercaptobutanoic acid, 2-Amino-4-mercaptobutyric acid, 2-amino-4-sulfanylbutanoic acid, D,L-Homocysteine, Homocysteine, dl-, (+-)-Homocysteine, USAF B-12, (+/-)-Homocysteine, Butyric acid, 2-amino-4-mercapto-, DL-, DL-2-Amino-4-mercaptobutyric acid, DL-Homocysteine, 90%, S7IJP4A89K, DL-Homocysteine (free base), DL-Homocysteine, 90per cent, 454-28-4, CHEBI:17230, NSC-206252, EINECS 207-222-9, UNII-S7IJP4A89K, NSC 206252, BRN 5493225, Butanoic acid, 2-amino-4-mercapto-, Homocysteine #, MFCD00004898, bmse000430, Butyric acid, 2-amino-4-mercapto-, DL- (9CI), SCHEMBL35836, CHEMBL310604, BDBM86202, CAS_778, DTXSID70859946, NSC_778, HOMOCYSTEINE DL-FORM [MI], NSC43117, DL-Homocysteine, analytical standard, NSC118376, NSC206252, s2994, XH1557, AKOS009156824, DL-Homocysteine, >=95% (titration), CS-W021561, FH38656, HY-W040821, AS-56604, SY026382, DB-020435, DB-050655, H0159, NS00014832, EN300-49129, C05330, D90809, Q192466, 1C51025E-77A8-4D48-8DC1-692A15D7F9D4 |
|---|---|
| Topological Polar Surface Area | 64.3 |
| Hydrogen Bond Donor Count | 3.0 |
| Inchi Key | FFFHZYDWPBMWHY-UHFFFAOYSA-N |
| Rotatable Bond Count | 3.0 |
| State | Solid |
| Substituent Name | Alpha-amino acid, Thia fatty acid, Amino fatty acid, Fatty acyl, Fatty acid, Monocarboxylic acid or derivatives, Carboxylic acid, Alkylthiol, Hydrocarbon derivative, Primary amine, Organosulfur compound, Organooxygen compound, Organonitrogen compound, Primary aliphatic amine, Carbonyl group, Amine, Aliphatic acyclic compound |
| Synonyms | (+-)-homocysteine, (2S)-2-amino-4-sulfanylbutanoic acid, (S)-2-amino-4-mercapto-Butanoate, (S)-2-amino-4-mercapto-Butanoic acid, 2 amino 4 mercaptobutyric acid, 2-amino-4-mercapto-Butanoate, 2-amino-4-mercapto-Butanoic acid, 2-amino-4-mercapto-Butyric acid, 2-amino-4-mercapto-DL-Butyrate, 2-amino-4-mercapto-DL-Butyric acid, 2-amino-4-Mercaptobutyrate, 2-Amino-4-mercaptobutyric acid, 2-Amino-4-mercaptobutyric acid (VAN), 2-amino-4-sulfanylbutanoate, 2-amino-4-sulfanylbutanoic acid, Butanoic acid, 2-amino-4-mercapto-, Butanoic acid, 2-amino-4-mercapto- (VAN), Butanoic acid, 2-amino-4-mercapto-, (S)-, Butyric acid, 2-amino-4-mercapto-, Butyric acid, 2-amino-4-mercapto-, DL-, Butyric acid, 2-amino-4-mercapto-, DL- (9CI), Butyric acid, 2-amino-4-mercapto-, L-, D,l-homocysteine, DL-2-amino-4-mercapto-Butyric acid, DL-2-Amino-4-mercaptobutyric acid, DL-homocysteine, DL-homocysteine (free base), Hcy, Homo-CYS, Homocysteine, Homocysteine (van), Homocysteine, l isomer, Homocysteine, l-, Homocysteine, l-isomer, L-2-amino-4-mercapto-Butyric acid, l-2-amino-4-mercaptobutyric acid, L-isomer homocysteine, Usaf b-12 |
| Heavy Atom Count | 8.0 |
| Pathway Kegg Map Id | map00260, map00350, map00270 |
| Compound Name | DL-Homocysteine |
| Kingdom | Organic compounds |
| Description | A high level of blood serum homocysteine is a powerful risk factor for cardiovascular disease. Unfortunately, one study which attempted to decrease the risk by lowering homocysteine was not fruitful. This study was conducted on nearly 5000 Norwegian heart attack survivors who already had severe, late-stage heart disease. No study has yet been conducted in a preventive capacity on subjects who are in a relatively good state of health., Elevated levels of homocysteine have been linked to increased fractures in elderly persons. The high level of homocysteine will auto-oxidize and react with reactive oxygen intermediates and damage endothelial cells and has a higher risk to form a thrombus. Homocysteine does not affect bone density. Instead, it appears that homocysteine affects collagen by interfering with the cross-linking between the collagen fibers and the tissues they reinforce. Whereas the HOPE-2 trial showed a reduction in stroke incidence, in those with stroke there is a high rate of hip fractures in the affected side. A trial with 2 homocysteine-lowering vitamins (folate and B12) in people with prior stroke, there was an 80% reduction in fractures, mainly hip, after 2 years. Interestingly, also here, bone density (and the number of falls) were identical in the vitamin and the placebo groups., Homocysteine is a sulfur-containing amino acid that arises during methionine metabolism. Although its concentration in plasma is only about 10 micromolar (uM), even moderate hyperhomocysteinemia is associated with increased incidence of cardiovascular disease and Alzheimer's disease. Elevations in plasma homocysteine are commonly found as a result of vitamin deficiencies, polymorphisms of enzymes of methionine metabolism, and renal disease. Pyridoxal, folic acid, riboflavin, and Vitamin B(12) are all required for methionine metabolism, and deficiency of each of these vitamins result in elevated plasma homocysteine. A polymorphism of methylenetetrahydrofolate reductase (C677T), which is quite common in most populations with a homozygosity rate of 10-15 %, is associated with moderate hyperhomocysteinemia, especially in the context of marginal folate intake. Plasma homocysteine is inversely related to plasma creatinine in patients with renal disease. This is due to an impairment in homocysteine removal in renal disease. The role of these factors, and of modifiable lifestyle factors, in affecting methionine metabolism and in determining plasma homocysteine levels is discussed. Homocysteine is an independent cardiovascular disease (CVD) risk factor modifiable by nutrition and possibly exercise. Homocysteine was first identified as an important biological compound in 1932 and linked with human disease in 1962 when elevated urinary homocysteine levels were found in children with mental retardation. This condition, called homocysteinuria, was later associated with premature occlusive CVD, even in children. These observations led to research investigating the relationship of elevated homocysteine levels and CVD in a wide variety of populations including middle age and elderly men and women with and without traditional risk factors for CVD. (PMID 17136938, 15630149), Homocysteine is an amino acid with the formula HSCH2CH2CH(NH2)CO2H. It is a homologue of the amino acid cysteine, differing by an additional methylene (-CH2-) group. It is biosynthesized from methionine by the removal of its terminal C? methyl group. Homocysteine can be recycled into methionine or converted into cysteine with the aid of B-vitamins., Studies reported in 2006 have shown that giving vitamins [folic acid, B6 and B12] to reduce homocysteine levels may not quickly offer benefit, however a significant 25% reduction in stroke was found in the HOPE-2 study even in patients mostly with existing serious arterial decline although the overall death rate was not significantly changed by the intervention in the trial. Clearly, reducing homocysteine does not quickly repair existing structural damage of the artery architecture. However, the science is strongly supporting the biochemistry that homocysteine degrades and inhibits the formation of the three main structural components of the artery, collagen, elastin and the proteoglycans. Homocysteine permanently degrades cysteine disulfide bridges and lysine amino acid residues in proteins, gradually affecting function and structure. Simply put, homocysteine is a 'corrosive' of long-living proteins, i.e. collagen or elastin, or life-long proteins, i.e. fibrillin. These long-term effects are difficult to establish in clinical trials focusing on groups with existing artery decline. The main role of reducing homocysteine is possibly in 'prevention' but studies thus far have not found benefits from it, and some have actually seen increased risks from consuming B vitamins, leading them to conclude that supplementation is not recommended. |
| Exact Mass | 135.035 |
| Formal Charge | 0.0 |
| Monoisotopic Mass | 135.035 |
| Isotope Atom Count | 0.0 |
| Molecular Complexity | 86.1 |
| Hydrogen Bond Acceptor Count | 4.0 |
| Molecular Weight | 135.19 |
| Database Name | fooddb_chem_all;pubchem |
| Covalent Unit Count | 1.0 |
| Defined Atom Stereocenter Count | 0.0 |
| Iupac Name | 2-amino-4-sulfanylbutanoic acid |
| Total Atom Stereocenter Count | 1.0 |
| Total Bond Stereocenter Count | 0.0 |
| Class | Carboxylic acids and derivatives |
| Inchi | InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7) |
| Smiles | C(CS)C(C(=O)O)N |
| Xlogp | -3.4 |
| Superclass | Organic acids and derivatives |
| Defined Bond Stereocenter Count | 0.0 |
| Subclass | Amino acids, peptides, and analogues |
| Molecular Formula | C4H9NO2S |
- 1. Outgoing r'ship
FOUND_INto/from Spinacia Oleracea (Plant) Rel Props:Source_db:fooddb_chem_all